152 related articles for article (PubMed ID: 32062455)
1. A High-Throughput Small Molecule Screen Identifies Ouabain as Synergistic with miR-34a in Killing Lung Cancer Cells.
Rupaimoole R; Yoon B; Zhang WC; Adams BD; Slack FJ
iScience; 2020 Feb; 23(2):100878. PubMed ID: 32062455
[TBL] [Abstract][Full Text] [Related]
2. Identification and validation of microRNAs that synergize with miR-34a - a basis for combinatorial microRNA therapeutics.
Orellana EA; Li C; Lisevick A; Kasinski AL
Cell Cycle; 2019 Aug; 18(15):1798-1811. PubMed ID: 31258013
[TBL] [Abstract][Full Text] [Related]
3. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene.
Cole KA; Attiyeh EF; Mosse YP; Laquaglia MJ; Diskin SJ; Brodeur GM; Maris JM
Mol Cancer Res; 2008 May; 6(5):735-42. PubMed ID: 18505919
[TBL] [Abstract][Full Text] [Related]
4. Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer.
Zhao J; Guerrero A; Kelnar K; Peltier HJ; Bader AG
Lung Cancer; 2017 Jun; 108():96-102. PubMed ID: 28625657
[TBL] [Abstract][Full Text] [Related]
5. miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner.
Bandi N; Vassella E
Mol Cancer; 2011 May; 10():55. PubMed ID: 21575235
[TBL] [Abstract][Full Text] [Related]
6. The RNA-binding protein SART3 promotes miR-34a biogenesis and G
Sherman EJ; Mitchell DC; Garner AL
J Biol Chem; 2019 Nov; 294(46):17188-17196. PubMed ID: 31619517
[TBL] [Abstract][Full Text] [Related]
7. In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation.
Cortez MA; Valdecanas D; Niknam S; Peltier HJ; Diao L; Giri U; Komaki R; Calin GA; Gomez DR; Chang JY; Heymach JV; Bader AG; Welsh JW
Mol Ther Nucleic Acids; 2015 Dec; 4(12):e270. PubMed ID: 26670277
[TBL] [Abstract][Full Text] [Related]
8. microRNA-34a as a Therapeutic Agent against Human Cancer.
Saito Y; Nakaoka T; Saito H
J Clin Med; 2015 Nov; 4(11):1951-9. PubMed ID: 26580663
[TBL] [Abstract][Full Text] [Related]
9. MiR-34a modulates ionizing radiation-induced senescence in lung cancer cells.
He X; Yang A; McDonald DG; Riemer EC; Vanek KN; Schulte BA; Wang GY
Oncotarget; 2017 Sep; 8(41):69797-69807. PubMed ID: 29050242
[TBL] [Abstract][Full Text] [Related]
10. Co-delivery of 5-fluorouracil and miRNA-34a mimics by host-guest self-assembly nanocarriers for efficacious targeted therapy in colorectal cancer patient-derived tumor xenografts.
Xu J; Zhang G; Luo X; Wang D; Zhou W; Zhang Y; Zhang W; Chen J; Meng Q; Chen E; Chen H; Song Z
Theranostics; 2021; 11(5):2475-2489. PubMed ID: 33500737
[No Abstract] [Full Text] [Related]
11. MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma.
Tivnan A; Tracey L; Buckley PG; Alcock LC; Davidoff AM; Stallings RL
BMC Cancer; 2011 Jan; 11():33. PubMed ID: 21266077
[TBL] [Abstract][Full Text] [Related]
12. microRNA-34a sensitizes lung cancer cell lines to DDP treatment independent of p53 status.
Wang X; Dong K; Gao P; Long M; Lin F; Weng Y; Ouyang Y; Ren J; Zhang H
Cancer Biother Radiopharm; 2013 Feb; 28(1):45-50. PubMed ID: 23036084
[TBL] [Abstract][Full Text] [Related]
13. The microRNA miR-34a inhibits non-small cell lung cancer (NSCLC) growth and the CD44hi stem-like NSCLC cells.
Shi Y; Liu C; Liu X; Tang DG; Wang J
PLoS One; 2014; 9(3):e90022. PubMed ID: 24595209
[TBL] [Abstract][Full Text] [Related]
14. Acacetin inhibited non-small-cell lung cancer (NSCLC) cell growth via upregulating miR-34a in vitro and in vivo.
Li J; Zhong X; Zhao Y; Shen J; Xiao Z; Pilapong C
Sci Rep; 2024 Jan; 14(1):2348. PubMed ID: 38287075
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-34a/EGFR axis plays pivotal roles in lung tumorigenesis.
Li YL; Liu XM; Zhang CY; Zhou JB; Shao Y; Liang C; Wang HM; Hua ZY; Lu SD; Ma ZL
Oncogenesis; 2017 Aug; 6(8):e372. PubMed ID: 28825720
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-34a Suppresses Autophagy in Alveolar Type II Epithelial Cells in Acute Lung Injury by Inhibiting FoxO3 Expression.
Song L; Zhou F; Cheng L; Hu M; He Y; Zhang B; Liao D; Xu Z
Inflammation; 2017 Jun; 40(3):927-936. PubMed ID: 28321785
[TBL] [Abstract][Full Text] [Related]
17. ROS-Responsive Polymeric Micelles for Triggered Simultaneous Delivery of PLK1 Inhibitor/miR-34a and Effective Synergistic Therapy in Pancreatic Cancer.
Xin X; Lin F; Wang Q; Yin L; Mahato RI
ACS Appl Mater Interfaces; 2019 Apr; 11(16):14647-14659. PubMed ID: 30933478
[TBL] [Abstract][Full Text] [Related]
18. miR-34a-dependent overexpression of Per1 decreases cholangiocarcinoma growth.
Han Y; Meng F; Venter J; Wu N; Wan Y; Standeford H; Francis H; Meininger C; Greene J; Trzeciakowski JP; Ehrlich L; Glaser S; Alpini G
J Hepatol; 2016 Jun; 64(6):1295-304. PubMed ID: 26923637
[TBL] [Abstract][Full Text] [Related]
19. Developing folate-conjugated miR-34a therapeutic for prostate cancer treatment: Challenges and promises.
Li WJ; Wang Y; Liu X; Wu S; Wang M; Turowski SG; Spernyak JA; Tracz A; Abdelaal AM; Sudarshan K; Puzanov I; Chatta G; Kasinski AL; Tang DG
bioRxiv; 2024 Jan; ():. PubMed ID: 38045265
[TBL] [Abstract][Full Text] [Related]
20. Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression.
Shi S; Han L; Deng L; Zhang Y; Shen H; Gong T; Zhang Z; Sun X
J Control Release; 2014 Nov; 194():228-37. PubMed ID: 25220161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
